Project Grant R21AI188166
Award Date
7/8/25
Completion Date
6/30/27
Dollars Obligated
$439K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This Project Grant award of $734,184 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to elucidate the mechanisms of parainfluenza virus genome replication. The primary awardee, Trustees of Boston University, will conduct structure-guided analysis of the viral polymerase complex to understand how it regulates the balance between transcription and replication. The team will also investigate how viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $605,778 to The Ohio State University to elucidate how influenza A viruses (IAV) manipulate the cellular protein ARIH2 to promote viral replication in airway epithelial cells. The research aims to uncover ARIH2 as a novel IAV restriction factor exploited by the virus, and evaluate ARIH2's potential as a therapeutic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The purpose of this 2-year grant, with a start date of January 23, 2025, is to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BnAbs) for their potential use in a universal influenza vaccine. The research will assess factors such as precursor frequency,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,170,096.00 to New York University School of Medicine to develop and optimize a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy. The key objectives are: (1) investigating the mechanism of action of the L7AE protein on various Orthomyxoviridae family members, (2) characterizing a transgenic mouse...
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of California, San Diego (UCSD) to investigate the mechanisms regulating immunoglobulin gene rearrangement. The research aims to determine how enhancers and epigenetic modifications orchestrate chromatin dynamics and spatial confinement to enrich interactions between variable...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,085,097.00 to the University of Wisconsin - Madison to study the role of cryptic influenza virus proteins in viral replication and pathogenesis. The research aims to characterize the interference activity and mechanism of action of these previously unknown viral proteins, define the full repertoire of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 - Allergy and Infectious Diseases Research, is providing $146,922.00 to Emory University to conduct research on factors that modulate the efficiency of influenza A virus (IAV) infection. The research aims to examine the relationship between the intensity of IAV exposure and infection diversity under distinct modes of exposure (intranasal vs. aerosol). Additionally, the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...
This Cooperative Agreement awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,352,292 in funding to the University of Illinois to conduct high-resolution profiling and computational modeling of influenza virus-immune dynamics during natural infection. The key objectives are to: (1) identify reliable immune correlates of reduced viral shedding and transmission risk, and...